Cjc 1295 Dac Prijs

Direct Assessment: Evaluating CJC 1295 DAC Prijs and Research Procurement

The baseline CJC 1295 DAC prijs for high-grade research compounds varies depending on analytical verification, synthesis scale, and sequence purity. Laboratories evaluating market pricing must account for full-spectrum testing—including HPLC purity, mass spectrometry sequence confirmation, and endotoxin quantification—rather than unverified gross weight alone.

In experimental settings, unverified or low-cost reagents frequently contain truncated peptide sequences, residual TFA (trifluoroacetic acid), or high endotoxin levels that compromise cell culture viability and invalidate in vivo signaling data. Obtaining standardized CJC-1295 DAC from established USA synthesis facilities guarantees lot-to-lot consistency, preventing costly experimental failures caused by degraded or misidentified GHRH analogs.

Chemical Structure and the Mechanism of Drug Affinity Complex (DAC)

CJC-1295 with DAC is a synthetic 30-amino-acid peptide derivative of Growth Hormone Releasing Hormone (GHRH 1-29) modified with a bioconjugates reactive group. Specifically, it incorporates a maleimido-propionic acid (MPA) linker covalently bound to the lysine residue at position 30. This structural modification allows the peptide to selectively undergo a bi-molecular nucleophilic substitution with circulating serum albumin post-administration in preclinical animal models.

Endogenous GHRH exhibits a very short biological half-life (typically 5 to 12 minutes) in circulation due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidases. By forming a covalent bond with endogenous albumin—a abundant serum protein with an extended half-life—CJC-1295 DAC avoids enzymatic cleavage and renal clearance. Preclinical studies suggest that this bioconjugation extends the functional elimination half-life of the compound to approximately 6 to 8 days in rodent models, permitting sustained receptor activation without requiring continuous micro-infusion setups.

Upon binding to the GHRH receptor (GHRH-R) on pituitary somatotropes, CJC-1295 DAC initiates a G-protein coupled receptor (GPCR) cascade. This activates adenylate cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP) and stimulating protein kinase A (PKA). This signaling path triggers downstream transcription factors responsible for growth hormone (GH) gene expression and regulated exocytosis.

Preclinical Literature: Sustained GH and IGF-1 Upregulation in Tissue Repair

In vivo research models investigating GHRH agonists have demonstrated that CJC-1295 DAC maintains elevated baseline levels of both GH and Insulin-like Growth Factor 1 (IGF-1). Unlike native GHRH, which yields sharp, transient GH pulses, the continuous receptor occupancy permitted by the DAC moiety establishes a elevated plateau of circulating IGF-1.

In preclinical studies evaluating musculoskeletal and soft tissue repair, sustained IGF-1 transcription has been linked to accelerated satellite cell activation, enhanced collagen type I and III deposition, and increased skeletal muscle protein synthesis. Researchers utilizing rodent models of ischemia, muscular trauma, or localized tendon injury frequently analyze how prolonged IGF-1 exposure influences cell proliferation and extracellular matrix (ECM) remodeling.

Furthermore, in vitro data indicate that GHRH receptor activation extends beyond the anterior pituitary. Extrapituitary GHRH receptors expressed in cardiac tissue, cutaneous fibroblasts, and vascular endothelial cells respond to GHRH agonists by upregulating anti-apoptotic signaling pathways (such as Akt/mTOR) and promoting capillary tube formation in endothelial cell migration assays. Explore broader mechanisms across our GHRH research hub for detailed pathway mapping.

Comparative Analysis: CJC-1295 DAC vs. Related GHRH Analogs

When designing comparative secretagogue studies, researchers must distinguish between long-acting and short-acting GHRH derivatives. Below is a comparative overview of primary GHRH analogs frequently integrated into cellular and animal research protocols:

CJC-1295 DAC features an MPA linker that confers covalent albumin-binding capability, extending its elimination half-life to several days and producing sustained, baseline elevation of GH and IGF-1. In contrast, CJC-1295 No DAC (also known as Modified GRF 1-29) lacks the reactive linker, resulting in a short half-life (approx. 30 minutes) that generates sharp, episodic GH spikes similar to physiological secretion.

Earlier GHRH fragments like Sermorelin represent the truncated 29-amino-acid active core of native GHRH, exhibiting rapid enzymatic inactivation by DPP-IV unless chemically modified. Conversely, advanced synthetic variants like Tesamorelin include a trans-3-hexenoic acid modification engineered specifically for high stability and metabolic lipolysis research. Additionally, researchers investigating synergistic secretagogue pathways often combine GHRH analogs with selective ghrelin receptor agonists such as Ipamorelin to evaluate co-activation of pituitary pathways.

Quality Verification Criteria: Ensuring Material Integrity Behind the Price

The primary variable driving CJC 1295 DAC prijs differences across global vendors is the rigor of quality control applied during solid-phase peptide synthesis (SPPS) and post-purification processing. Laboratories seeking reproducible assay outcomes must verify several key analytical metrics before procurement:

1. High-Performance Liquid Chromatography (HPLC): RP-HPLC chromatograms must demonstrate a primary peak purity of ≥98.0%. Trace impurities, such as failure sequences or deletions, alter receptor binding kinetics and confound binding affinity assays. 2. Electrospray Ionization Mass Spectrometry (ESI-MS): Mass spectrometry verifies exact molecular weight (CJC-1295 DAC theoretical mass: ~3647.95 Da). ESI-MS confirms the successful addition of the maleimide linker and rules out sequence truncation. 3. Endotoxin Testing: Bacterial endotoxins (lipopolysaccharides) induce severe inflammatory responses in cellular cultures and animal models. High-grade research compounds must undergo Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels below 0.1 EU/mg. 4. Trifluoroacetic Acid (TFA) Content Analysis: Standard SPPS uses TFA for cleavage. Residual TFA can exhibit cytotoxic effects in cell culture assays. Quality-focused suppliers utilize counter-ion exchange (e.g., acetate conversion) to ensure safe in vitro handling.

PX1 Research ensures that every batch undergoes complete independent analysis. Researchers can review lot-specific documentation directly via our PX1 research portal or obtain bulk specifications through our wholesale account program.

Reconstitution Protocols for Laboratory Investigation

Proper handling and reconstitution of lyophilized CJC-1295 DAC are essential to preserve the structural integrity of the maleimide functional group. Exposure to improper pH or shear forces can compromise the DAC moiety's reactivity prior to albumin conjugation.

Reconstitution should take place in a sterile laminar flow hood. For standard laboratory applications, Bacteriostatic Water (0.9% benzyl alcohol) or sterile physiological saline is introduced along the internal glass vial wall to prevent vigorous agitation. The vial should be gently swirled until the cake is fully dissolved; mechanical vortexing must be avoided as it induces protein denaturing and aggregation.

Because CJC-1295 DAC is designed to undergo nucleophilic reaction with primary thiols, researchers preparing stock solutions for in vitro work must carefully manage buffer selection. Buffers containing free thiol donors (such as DTT or BME) must be avoided, as they will react prematurely with the MPA linker before target binding studies occur.

Storage and Stability Specifications

Lyophilized CJC-1295 DAC powder displays high thermodynamic stability when stored under controlled environment conditions. For long-term preservation, sealed vials should be kept at -20°C to -80°C in a desiccated freezer environment, protected from direct light exposure.

Following reconstitution, the liquid solution should be maintained at 2°C to 8°C and utilized within an established experimental window (typically 21 to 28 days when preserved with antimicrobial agents). Repeated freeze-thaw cycles must be strictly avoided, as thermal cycling causes peptide cleavage and precipitation. Laboratories requiring periodic sampling should divide the stock solution into single-use aliquots using sterile microcentrifuge tubes prior to initial freezing.

To review structural specifications for our entire inventory of metabolic and pituitary secretagogues, access our catalog of all research peptides.

Assay Design: Evaluating CJC-1295 DAC in Cellular and Animal Models

In preclinical study design, CJC-1295 DAC is frequently utilized to evaluate systemic growth factor regulation, muscle hypertrophic signaling pathways, and tissue repair kinetics. Researchers measuring receptor-mediated responses commonly monitor downstream biomarkers such as total serum IGF-1 concentrations, IGFBP-3 binding protein levels, and phosphorylated Akt/mTOR proteins in target tissues.

In cell culture models, investigators assess how persistent GHRH receptor stimulation impacts pituitary cell transcription profiles, evaluating potential receptor desensitization or downregulation over extended culture periods. Measuring transcription rates of key myogenic factors (such as MyoD and Myogenin) in primary satellite cell cultures provides quantitative data on tissue repair capability under sustained GHRH stimulation.

By sourcing fully validated reagents with transparent batch verification, research teams eliminate variables related to compound degradation, ensuring that observed physiological alterations correlate directly to compound activity rather than synthesis artifacts.